Company intelligence / Profile preview

Perception Neuroscience

New York, New York, United Statesperceptionns.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

Perception Neuroscience is developing PCN-101 (Arketamine/R-ketamine), currently in Phase 2a proof-of-concept clinical trials for Treatment-Resistant Depression. Phase 1 multiple ascending dose PK study in healthy volunteers was completed in 2020, and the US IND was approved in 2022.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesGlutamatergic modulator
Industry: Biotech

Drug pipeline

1 asset

r-ketamine

Partnerships

Otsuka Pharmaceuticals

Beyond the preview

Go deeper on Perception Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perception Neuroscience.